State Street Corp Neu Base Therapeutics, Inc. Transaction History

State Street Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	BUY	$1.26 - $2.95 $13,449 - $31,488	10,674 Added 18.4%	68,687 $129,000
Q3 2021 Nov 15, 2021	BUY	$3.27 - $4.76 $111,834 - $162,792	34,200 Added 143.62%	58,013 $209,000
Q2 2021 Aug 16, 2021	SELL	$4.63 - $7.34 $1.08 Million - $1.72 Million	-234,313 Reduced 90.77%	23,813 $114,000
Q1 2021 May 17, 2021	BUY	$6.92 - $12.36 $18,933 - $33,816	2,736 Added 1.07%	258,126 $1.91 Million
Q4 2020 Feb 16, 2021	SELL	$6.92 - $9.25 $154,004 - $205,858	-22,255 Reduced 8.02%	255,390 $1.79 Million

Q3 2020 Nov 10, 2020	BUY	$7.25 - $9.71 $209,162 - $280,133	28,850 Added 11.6%	277,645 $2.11 Million
Q2 2020 Aug 14, 2020	BUY	$6.69 - $11.51 $1.66 Million - $2.86 Million	248,795 New	248,795 $2.18 Million

Ticker NBSE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,258,700
Description
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.